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Background – All solid organ transplanted patients are treated with immuno suppression 
medications to keep the immune system from rejecting the transplanted organ. Unfortunately 
the suppressed immune system makes the body more exposed for cancer and opportunistic 
infections. Among the most important viruses that causes one of these opportunistic infections 
is cytomegalovirus (CMV). A local project showed that not all transplanted patients on CMV 
prophylaxis get the right dose according to creatinine clearance (CrCl), and that the patients 
who had not been prescribed the recommended dose according to CrCl had a higher incident 
of CMV disease than those adjusted as recommended. The Quality improvement team for the 
transplant unit therefore suggested that a project could further investigate these issues. 
Aim and objectives – The aim of this project was to critically review and evaluate the 
processes in the prescribing and administration of valganciclovir for cytomegalovirus 
prophylaxis in liver, kidney or pancreas transplantation. 
Methods – Semi-structured one-to-one interviews with 2 nurses and 6 prescribers were 
conducted to establish current practice in prescribing, administration and monitoring of 
valganciclovir. A review of the local protocols at the transplant unit was conducted. To assess 
the harm a database analysis on the incident reporting system and a retrospective review of 
clinical records of 4 patients was undertaken. A questionnaire was developed for staff to self-
assess the risk of harm of the whole process of CMV prophylaxis treatment. Pharmaceutical 
care issues relevant to CMV prophylaxis were recorded prospectively by clinical pharmacists 
over a two month period. 
Results – The semi-structured interviews with prescribers indicated that: 1) Prescribers often 
fail to recognise that the valganciclovir dose should be adjusted with changing CrCl. 2) That 
the laboratory test results taken at the clinic do not come back until the evening and are 
therefore not available at the time of prescribing, 3) There are gaps of knowledge, especially 
in the junior doctors. Reviews of local protocols suggested a need for update of the protocols 
and inclusion of detailed dosing guidance. The one incident reported in the database in terms 
of valganciclovir involved a missed dose. Case note reviews of four patients identified that 
dose adjustments are appropriate in 2 cases, 1 case was borderline and the other was a 
complex case but was judged to be appropriate. The questionnaire identified that there was 
agreement among healthcare professionals that there is a risk of errors that might lead to harm 
associated with all stages of valganciclovir use. Two clinical pharmacists recommended 
adjustment of valganciclovir 12 times in 7 patients in a time period of approximately two 
months.  
Conclusion – the outcomes from the interviews and pharmaceutical care issues analysis 
confirm the previous observation that the dose of valganciclovir is not always adjusted 
according to CrCl. Recommendations for improvement are to ensure modified guidelines are 
implemented to ensure all prescribers are aware of need for dose adjustment. Further work 
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1.1 Organ Transplantation  
Organ transplantation can be lifesaving for many patients with irreversibly damaged organs.  
Example of organs that can be replaced are kidney, liver and heart.[1]A transplanted organ is 
often referred to as a graft. UK figures from 2008-9 demonstrated that of 3513 organ 
recipients, 2552 received an organ from a deceased donor, and 961 from a living donor. Five 
year kidney graft survival rates are reported as 89 % for transplant from living donors, and 83 
% from both deceased heart beating donors (HBD) and deceased non-heart beating donors 
(NHBD). The patient survival rates following deceased heart beating donor liver 
transplantation are 90% after one year and 76% after five years. For pancreas the one year 
graft survival rates are 70%, for simultaneous kidney and pancreas (SPK) transplants the one 
year rates are 89%. [2]  
The Royal Infirmary of Edinburgh (RIE) performs kidney, liver and pancreatic 
transplantations. According to the annual report for East of Scotland Renal Transplantation 
Service there were  83 renal transplants with cadaver donor and 26 renal transplants with 
living donors performed at RIE in 2009-2010.[3] NHS Blood and Transplants (NHSBT) 
annual statistics showed that 667 liver transplantations with deceased donor were done in the 
UK in 2008-2009. Five hundred and thirty seven patients got a whole liver transplanted. 
There were also 27 living liver lobe donor transplants. Nineteen of these transplants were in 
pediatric patients and 8 in adult patients. NHSBTs statistics also showed that 171 pancreas 
transplants with a deceased heart beating donor were performed in 2008-2009, but out of 




Kidney transplantations are the most frequent type of transplantations performed in the 
UK.[2] Some of the most common reasons people need kidney transplantation is renal failure 
due to diabetes and hypertension.[4, 5] Liver transplant is the second most frequently 
performed.[2] The main reasons for needing a liver transplant are end stage liver disease due 
to hepatitis C cirrhosis or alcoholic cirrhosis. [6]  Pancreas transplantation can be done on 
people diagnosed with type-1 diabetes, but because the risk with this major surgery and the 
immunosuppressant drugs can be worse than living with diabetes, pancreas transplantation is 
therefore not standard treatment. Pancreas transplantation is usually performed in 
combination with kidney transplantations in patients with severe kidney damage, often caused 
by diabetes.[7, 8] In both kidney and pancreas transplantation the patient’s own organs are not 
removed from the body. [7, 9] 
 
1.2 Immuno suppression 
The immune system protects the body from harm by destroying foreign bodies. 
Unfortunately, the immune system cannot separate the harmful bodies such as bacteria and 
viruses from the transplanted organ which is also foreign to the body. To keep the immune 
system from destroying the organ,  transplant patients are prescribed immuno suppression 
medications[10]. Hence the incidence of graft rejection in transplanted patients has been 
reduced. Unfortunately, the use of immuno suppressants also comes with serious side effects 
such as increased risk of infections and cancer. Immuno suppression agents can be divided 
into various groups depending on their mechanism of action.  To increase the immune 
suppressant effect and reduce the side effects the various groups are usually combined. [10] It 
is important to not suppress the immune system too much but to maintain a balance. Too 
much suppression would cause a higher than necessary risk of infections and cancer. When 
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the body has a suppressed immune system it can be infected with ordinary bacteria, viruses, 
fungi and some pathogens which do not usually affect people with normal immune systems, 
these are called "opportunistic infections”. Among the most important virus that causes one of 
these so called opportunistic infections is cytomegalovirus (CMV).[10]  
 
1.3 Cytomegalovirus  
Cytomegalovirus (CMV) belongs to the herpes viruses-family. Once a person is infected with 
CMV, he will always have CMV in his body.[11] Transmission occurs from direct person-to-
person contact, via body fluids.[12] The prevalence to CMV is close to 100 percent in 
developing countries[13], while in the United states between 50 and 80 % of adults will be 
affected with CMV by the time they reach 40.[14]  
Most of the time the virus will be inactive, but it can be reactivated and cause CMV-disease. 
Reactivation may happen as a result of either a disease like cancer or AIDS, or it can happen 
due to treatment with immune suppressive drugs or chemotherapy. CMV is for most people 
harmless, but for immune compromised patients, for example people on immunosuppressant 
drugs, it can be deadly.[15] The virus can attack different body parts as for example 
oesophagus, stomach, intestine, lungs or eyes. Symptoms that may appear in patients with 
CMV disease can be fever, night sweats, weakness, sore throat, fatigue, and swollen glands. 
[16] 
An organ transplantation with a CMV-positive donor can cause a CMV-negative recipient to 
develop CMV disease, and a reactivation in a those recipients who already are CMV-positive. 
Despite the risk in transplanting a CMV-positive organ, this is not contraindicated and is 
adopted in practice due to a high prevalence of CMV in the population and shortage of 
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organs. Recent studies also show that implementation of effective antiviral prophylaxis 
treatment can give a successful outcome. [17, 18] 
 
1.4 CMV prophylaxis and treatment 
1.4.1 Choice of prophylaxis agent 
 Ganciclovir and valganciclovir, a prodrug for ganciclovir, remain the most used treatment 
options for prevention and treatment of CMV disease, even though they are expensive and 
toxic. Aciclovir and its prodrug valaciclovir are both used less frequently for CMV 
prophylaxis in solid organ transplant (SOT) patients. Some studies show little or no benefit 
from prophylaxis with aciclovir in renal transplant patients. This means it may be used in 
recipients with low risk CMV profile. It is not effective in liver patients.[19] Foscarnet and 
cidofovir are used for treatment of active CMV disease if the patient does not respond to 
ganciclovir treatment, but are less used alternatives because of renal toxicity.[20] They are not 
recommended for treatment of CMV infections other than retinitis in AIDS patients.[21, 22] 
Studies comparing efficacy and safety of valganciclovir against oral ganciclovir of CMV 
prophylaxis show that valganciclovir has no superior efficacy only that it causes more 
neutropenia compared to other agents.[23, 24]  
A randomised, prospective, double-blind, double-dummy study compared the efficacy and 
safety of valganciclovir with oral ganciclovir as CMV prophylaxis in 364 SOT patients where 
the recipients were CMV- negative and the donors CMV-positive. Two hundred and thirty 
nine patients was randomised to the valganciclovir group and 125 patients randomised to the 
ganciclovir group. End-points analyzed included were if the patients developed CMV disease, 
acute rejection and safety of valganciclovir. The endpoints were checked after 6 and 12 
months. CMV disease developed in 12.1% of valganciclovir patients and in 15.2% of 
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ganciclovir patients by 6 months. By 12 months, the incidences were 17.2% in valganciclovir 
patients and 18.4% in ganciclovir patients. Acute allograft rejection was lower with 
valganciclovir. After 6 months 29.7 % of the valganciclovir group had experienced acute graft 
rejection, compared to the ganciclovir group with 36 %. After 12 months the difference 
between the two groups had decreased. For valganciclovir the percent was 32.6 and for 
ganciclovir 35.6%. The safety profile was similar for both drugs except from the incident of 
neutropenia which was higher in valganciclovir patients (8.2 %) than in ganciclovir patients 
(3.2 %). The researcher conclusion was that “valganciclovir was as clinically effective as oral 
ganciclovir with a comparable safety profile”[23]   
 
A meta-analysis of CMV prophylaxis in solid organ transplanted (SOT) patients compared 
valganciclovir with other agents, mainly ganciclovir. The background for this study was that 
the writers suspected that valganciclovir was not more efficient or safer than the other 
treatment alternatives, despite it being most the commonly used and the most expensive. The 
results from this analysis did not find that valganciclovir was more efficient than the other 
treatment therapies, but it did find that the risk for neutropenia and CMV late-onset disease 
was higher with valganciclovir. 
The research group behind the study suggest several reason for valganciclovir popularity: 
“The reasons for this popularity are multifactorial, including the convenience of once daily 
dosing, limitations on the production of oral ganciclovir, and influential marketing strategies 







Table 1 CMV prophylaxis and treatment options in SOT patients[19] 
Drug Prophylaxis Treatment 
Ganciclovir (IV)  
Valganciclovir (oral)  
Aciclovir   
Valaciclovir   
Cidofovir  
Foscarnet   
   
 
1.4.2 Treatment duration 
An international, randomized, prospective, double-blinded study was conducted to compare 
prophylaxis treatment with valganciclovir for 200 days with treatment for 100 days in CMV 
negative patients who had received a CMV positive graft. Two years after they had been 
transplanted, CMV had occurred in 21.3% of the group that was treated for 200 days, while 
among the patients treated for 100 days 38.7% developed CMV disease.  One hundred percent 
of the patients treated for 200 days survived compared to 97 % in the other group. The rates 
of graft loss and acute rejection rates were comparable in both groups. The 200-day group had 
acute rejection in 11.6% of the patients vs. 17.2% for the 100 days group. The graft loss rates 
were 1.9% for the 200 days group and 4.3% in the 100-days group. The research group 
concluded that “Extending valganciclovir prophylaxis from 100 to 200 days is associated with 
a sustained reduction in CMV disease up to 2 years post transplant.” [25] Six months 
prophylaxis with valganciclovir together with a one-time determination of viremia have 
shown to be cost effective compared to three months prophylaxis. [26] 
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No other agents for CMV prophylaxis is specifically licensed for treatment for 200 days, but 
the SPC to valaciclovir states that the treatment may need to be extended beyond 3 months 
and the costs were therefore compared to the costs of valganciclovir 200 days. The expenses 
were lower for the valaciclovir treatment. [27]  
1.4.3 Complications with present treatment option.  
As mentioned earlier CMV is an important problem in SOT patients. The increased 
accessibility of antiviral therapies has reduced the development of CMV disease, but it has 
also caused other problems such as ganciclovir resistance, late-onset CMV disease, and 
insecurity about most favourable treatment duration of CMV prophylaxis and treatment. [28] 
A study conducted on SOT recipients and the emergence of ganciclovir-resistance CMV 
disease showed that 2.1 % of the SOT recipients in the study developed ganciclovir-resistant 
cytomegalovirus disease. Five out of 67 (7%) CMV-negative recipients who received a CMV-
positive organ developed a CMV disease with resistance against ganciclovir. None of the 173 
CMV-positive recipients developed ganciclovir-resistant CMV disease.[29] 
A study was conducted in 2001 regarding prevalence on late onset CMV disease. The study 
showed that most of the CMV disease episodes happened between 3 and 6 months post 
transplantation. The study included 37 liver and kidney transplanted patients. The recipients 
were CMV-negative with CMV-positive donors and they were treated prophylactically with 
oral ganciclovir 100 days after transplantation. The probabilities of acquiring CMV disease 
were 0% at 3 months, 23.7% at 6 months and 27% at 12 months.[30] 
There is general agreement that prevention is the best treatment option against CMV in solid-
organ transplants recipients, but all the antiviral treatment options are more or less toxic. A 
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solution may be development of a vaccine.[28] Several CMV vaccines are in various stages of 
development, but none are currently available.[31] 
1.4.4 Valganciclovir 
Valganciclovir is absorbed from the gastrointestinal tract and quickly metabolised to 
ganciclovir. Ganciclovir is a synthetic analogue of 2'-deoxyguanosine. Ganciclovir is 
phosphorylated to ganciclovir triphosphate and inhibits viral DNA synthesis by competing 
with deoxyguanosine triphosphate. Ganciclovir triphosphate is incorporated into viral DNA, 
Viral DNA elongation is terminated and replication of herpes viruses is inhibited. [32, 33] 
Viruses sensitive for this drug include Human Cytomegalovirus (HCMV), Epstein-Barr virus 
(EBV), hepatitis B virus (HBV) and several of the herpes viruses.  For patients who have 
received a solid organ transplant, the recommended dose is according to the SPC 900 mg once 
a day, starting within 10 days of transplantation and the treatment should last until 100 days 
post-transplantation and 200 days in kidney-transplantation. Most of the drug is eliminated 
through renal excretion and the elimination is an important factor for interactions with other 
drugs [32] Ciclosporin and tacrolimus, which are used as immuno suppressant agents in 
transplanted patients, can impair kidney function[34, 35] and therefore placing patients at risk 
of toxicity from renal excreted medicines. Mycophenolate mofetil (MMF) competes with 
ganciclovir for tubular secretion and may increase concentrations of both substances.[36] 
Both of these types of interactions can lead to excessive exposure of ganciclovir and may be 
associated with serious adverse reactions. Severe leucopoenia, neutropenia, anaemia, 
thrombocytopenia, pancytopenia, bone marrow depression and aplastic anaemia have been 
associated with use of valganciclovir. Therefore, patients with renal impairment must have the 
dose adjusted according to renal function estimated by measurement of creatinine 
18 
 
clearance.[32] To decrease risk of toxicity regular haematological monitoring should also be 
undertaken to minimise risk of harm. CrCl can be calculated by the Cockcroft-Gault equation:  
 




Table 2 shows how the doses should be adjusted according to the calculated CrCl. 
Table 2: Dosage adjustments according to creatinine clearance in renal impaired 
patients.[32, 38] 
CrCl (ml/min) 
Valganciclovir dose for 
prophylaxis against CMV 
disease 
 ≥ 60 900 mg (2 tablets) once daily 
40 – 59 450 mg (1 tablet) once daily 
25 – 39 450 mg (1 tablet) every 2 days 
10 – 24 450 mg (1 tablet) twice a week 
 < 10 
100 mg three times a week 
after dialysis (liquid solution) 
 
Special precautions should be taken when handling this medicine. If tablets are crushed or 
broken they should be thrown away in special waste. Staff should not come in direct contact 
with the broken tablets because the tablets are considered possibly carcinogenic and 
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All guidelines are designed to minimise the potential for harm, but there is concern that in 
practice such guidelines are not closely followed. Reviews of methods for changing 
healthcare behaviours, indicates that mailing guidelines to targeted healthcare professionals 
and publishing them does not lead to changes in staff behaviour. Less passive methods of 
dissemination are necessary. It requires time, passion and resources to manage to disseminate 
and implement clinical guidelines. [39]  
If guidelines are not used, there is potential for harm especially when high risk medicines are 
used. This project will attempt to identify where practice can be improved to minimise harm 
to transplant patients receiving antiviral prophylaxis for CMV.  
The transplant unit at RIE has its own protocol in both liver and renal transplantation 
 
 
1.6 Scottish Patient Safety Alliance – Scottish Patient Safety Programme  
The topic for this project was chosen after discussion with the quality improvement team 
(QIT) at the transplant ward at RIE. The QIT is part of the clinical governance infra-structure 
which is in place to facilitate delivery of an organisational quality improvement programme. 
It integrates with the Scottish Patient Safety Programme (SPSP), which is a national 
programme developed to improve safety of hospital care in the National Health Service  
(NHS) in Scotland.[40] Compared to international standards, NHS Scotland provides overall 
good safety to patients, however, as for any organization, there are still errors happening 
20 
 
which can be avoided. To help address this the Scottish Patient Safety Alliance (SPSA) was 
established. This organisation co-ordinates the Scottish Patient Safety Programme.[41] A 
comparable safety programme was initiated in 3000 hospitals in the U.S and this has saved 
approximately 122,000 lives.[42] Research shows that ten percent of patients admitted to 
Scottish NHS- hospitals experience adverse events , and 50% of these events are most likely 
avoidable.[41] One of the tools the SPSP uses to improve the safety is the Model for 
Improvement.[43] the model has two parts, first it has three questions you should consider: 
- What are you trying to accomplish?  
- How will you know your change is an improvement?  
- What changes can you make that will result in improvement?  
The second part is the Plan-Do-Study-Act cycle which is used to test if you have 
accomplished improvement.  First you plan it, then you do it, then you observe the results and 





Figure 1 Model for improvement.[43] 
The International Conference on Harmonisation of Technical Requirements for Registration 
of Pharmaceuticals for Human Use defines adverse event as: “Any untoward medical 
occurrence that may present during treatment with a pharmaceutical product but which does 
not necessarily have a causal relationship with this treatment.” [45] Under the term adverse 
event belongs the term adverse drug event, which the institute of medicine defined as  “an 
injury resulting from medical intervention related to a drug.”[46] This can easily be confused 
with adverse drug reaction, which has the well-accepted definition “A response to a drug 
which is noxious and unintended and which occurs at doses normally used in man for  
prophylaxis, diagnosis, or therapy of disease or for modification of physiological 
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function.”[45]  To avoid adverse drug events which actually cause harm, medication errors 
are defined as  “Any preventable event that may cause or lead to inappropriate medication use 
or patient harm while the medication is in the control of the health care professional, patient, 
or consumer” also need to be eliminated.[47] Medication errors are the most common type of 
medical error happening in facilities. [48] Reducing medication errors will therefore be 
important to improve patient safety, and to this project.  
 
To eliminate medication errors you first have to identify when during the process incidents 
happens. The NHS uses an incident reporting system called Datix®. This system helps to map 
steps where things can go wrong. When reporting an adverse event in Datix® the incident has 
to be described, the reasons that this incident happened have to be investigated, and what 
action is taken in this particular case and what action is taken in general to prevent this from 
happening again need to be documented. Each incident requires information such as lessons 
learned from the incident, the drug, the severity of the adverse event, where it happened, the 
reporter and the category of event. Each speciality has a quality improvement team (QIT) 
which looks at Datix® and initiates measures to prevent adverse events.  
 
A retrospective study was recently conducted in the Netherlands to examine how many of 
adverse events found in patients’ record are reported in the hospital reporting systems. A 
database from a record review study was used; this included 14 hospitals and 5375 patients. In 
the records for these patients this research group identified 498 adverse events; only 18 of 
these events were also found in one or more of the reporting systems they searched through. 
This show that most healthcare workers unfortunately will not report adverse events into the 
incident reporting systems .[49] A survey conducted on staff at a nursing home shows that 
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important barriers for them to report errors are: fear of being blamed, time consuming, lack of 
recognition that a medication error has occurred and fear of disciplinary action.[50]  The NHS 
needs to encourage reporting and establish several methods for identifying quality 
improvement opportunities. A study called the CHUMS study - Care Homes Use of 
Medicines Study financed by the Department of Health in England investigated the 
prevalence type and underlying cause of errors in care homes. The results from this study 
showed that there were errors done throughout the whole process. The likelihood that there 
will be an error when prescribing something is 8.3%, for monitoring the percent is 14.7 %,  
9.8 % for dispensing and 8.4 % for administration. In this study prescribing and monitoring 
errors were picked up by clinical medication review by the pharmacist. Dispensing errors 
were picked up by visual checking the medicines and administration errors were picked up by 
observation of drug rounds.[51] In the transplant unit the clinical pharmacist and the 
pharmacy technicians carry out medication reviews on the patients admitted to the hospital 
(in-patients) and may pick up prescribing errors. Prescribing errors can also be picked up by 
other healthcare professionals. Dispensing errors may be picked up by the pharmacist or the 
pharmacist technician when they do a medication review for patients in the hospital and see 
review patients own drugs, or by the nurses during administration. There are no checkpoints 
(points in the process where errors can be detected before causing potential harm to patients) 
for either administration or monitoring of treatment after the patient is discharged. Some 
administration errors can be picked up by retrospective review of medicine charts, but not all 
errors can be detected that way. Errors may be picked up at the next clinic visit. 
 
Clinical pharmacy plays an important role in safe and effective use of medications.[52-55] 
This was demonstrated in a single-blind, standard care–controlled
 
study which investigated 
the impact of having a pharmacist present at ward rounds. The results showed that 
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preventable adverse drug events were reduced by 78 percent.[52] Another study done in an 
emergency department compared a group of patients where the pharmacist checked the 
medication orders with a group of patient with no pharmacist. The results was that the rate of 
errors was 16.09 per 100 medication orders for the control group compared with 5.38 per 100 
orders for the intervention group.[53] Also, a systematic review of thirty-six studies was done 
to evaluate the role of the clinical pharmacist and outcomes on in-patient adults. The review 
concluded that the addition of clinical pharmacist resulted in improved care and 
outcomes.[54] A randomized trial was conducted to determine if a pharmacist intervention 
would improve adherence in heart failure patients. These interventions included providing of 
verbal instructions and written materials to the patient about their medications. The 
conclusion of the study was that the interventions could improve adherence, but that the 
interventions probably had to be done constant to benefit.[55] 
 
Anecdotally it is recognized that pharmacists do not formally document all interventions they 
make.  
The Royal Pharmaceutical Society has made a set of guidelines for recording interventions. 
They have listed four main reasons for a pharmacist to record interventions they make: 
-  To ensure and improve patient care. 
- To provide evidence that the pharmacists contribution is of value.  
- To have a record available for examination on where decisions could be challenged  
- And to monitor incidents or near misses in prescribing, dispensing or administration of 







1.7 Why is it important to reduce medication errors?  
In addition to the obvious reasons in reducing harm and saving lives, elimination of 
medication errors can save the NHS a lot of money. The National Patient Safety Agency 
(NPSA) believes that more than £750 million is used each year in England on preventable 
harm from medicines [57] A study was conducted on adverse drug events in older patients in 
ambulatory settings. The study investigated incidence and preventability of adverse drug 
events. The study showed that most adverse events happened in the steps of prescribing 
(58.4%) and monitoring (60.8%), and they concluded that “Prevention strategies should target 
the prescribing and monitoring stages of pharmaceutical care”, which is the main focus steps 
in this project. Among the errors occurring in the prescribing stage were wrong therapeutic 
choice, wrong dose and not enough education about the medication to the patient. In the 
monitoring step example of errors found were failure to act on clinical findings or laboratory 
results and inadequate monitoring.[58] 
High risk medicines associated with medication errors have been the focus of many SPSP 
initiatives such as anticoagulants and insulin.[59] There are many other groups of medicines 
with potential for optimisation of prescribing to avoid medication errors and harm. Within the 
transplant unit one of these groups is CMV prophylaxis given to patients who have received 
an organ transplant. In immune compromised patients it is essential that CMV infection is 
prevented without toxic effects from the drugs.  
An important reason that the QIT suggested the evaluation of the processes of use of 
valganciclovir as prophylaxis in transplant patients was a local student project done on CMV. 
The project included 257 patients transplanted from Jan 2006 to May 2009 followed up at 4 
different hospitals (The Royal Infirmary of Edinburgh, the Aberdeen Royal Infirmary, 
Raigmore Hospital in Inverness and Ninewells Hospital in Dundee). One part of this project 
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investigated if the prescribing of valganciclovir was correct according to CrCl (calculated by 
the Cockcroft-Gault equation) and how incorrect prescribing affected the incidence of CMV 
disease. Ninety eight of the 257 (38%) patients in the study used valganciclovir and were 
included in this part of the study. Seventy nine of them were kidney transplanted patients and 
19 of them were simultaneously kidney and pancreas transplanted patients. At discharge, 46 
(58%) of the kidney patients received the correct dose according to their CrCl and 33 (42%) 
of the kidney patients were prescribed incorrect dose according to CrCl. Of the patients who 
received an incorrect dose 12 (36%) of them developed CMV disease, while only 5 (11%) of 
those who received the correct dose according to CrCl developed CMV disease. Three months 
after transplantation 8 out of the 33 (24%) patients who received incorrect doses at discharge 
still had not had their dose corrected. Two of these developed CMV disease. This study 
suggested that adjusting the Valganciclovir dose according to CrCl is not always done 
correctly and this increases the incident of CMV disease.[60] 
 
This project aims to evaluate the processes for prescribing, administrating and monitoring of 
Valganciclovir in patients who have received liver, kidney or pancreas transplantation with 
the intention of making recommendations to improve the use of this agent with the intention 










2 Aims and objectives 
 
2.1 Aim 
Critically review and evaluate the processes in the prescribing and administration of 
valganciclovir for cytomegalovirus prophylaxis in liver, kidney or pancreas transplantation. 
 
2.2 Objectives 
1. Define the processes for prescribing, administering and monitoring of valganciclovir 
use for CMV prophylaxis. 
2. Characterise the procedures available to support decisions in the use of valganciclovir. 
3. Characterise the harm assessment based on data from audit  
4. Investigate problems in the prescribing, administering and monitoring of 
valganciclovir by interviews with clinical staff.  
5. Characterise pharmaceutical care issues from prospective audit of pharmacists’ 
contributions.  
6. Critically evaluate opportunities for quality improvement by presentation of findings 




2.3 Subjects and settings 
2.3.1 Study design  
The project comprises semi-structured one-to-one interviews with prescribing staff and 
nurses, database analysis of reporting system Datix®, retrospective review of pharmaceutical 
interventions, self administered questionnaire for various healthcare professionals and a 
review of clinical records. 
2.3.2 Subjects and settings 
The transplant ward at the Royal Infirmary of Edinburgh has beds for 16 patients,  
additionally there are 5 beds in the High Dependency Unit (117). There is one team for 
kidney transplantation, and one for liver. The kidney- team also covers pancreas 
transplantations. The teams consist of a junior grade doctor, medical registrar, surgical 
registrar, consultant physician and consultant surgeon. The teams rotate regularly. Prescribers 
were categorised into junior grade doctors, middle grade doctors and senior grade doctors. 
The senior grade doctors consist of consultants, the middle grade doctors are registrars, and 
junior grade doctors are any doctor with less experience than a registrar.  
Once discharged patients are followed up in the out-patient clinic and can be seen by clinic 
nurses, a senior or middle grade doctor and a transplant-coordinator. The clinic runs several 
times a week for both liver- and kidney-transplanted patients. The frequency of appointments 
for each patient varies depending on the clinical picture and time since the transplantation.  
The project was undertaken in parallel with another student project which investigated 
prescribing and monitoring the use of immune suppression drugs. The project team consist of 
the investigator Sara Ann Dyrhaug, investigator for the parallel project Kinjal Patel, clinical 
supervisors Katherine Davidson and Scott Garden, and academic supervisor Moira Kinnear.  
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2.3.3 Inclusion criteria 
Convenience sampling was chosen to select staff for invitation to participate in interviews. 
The senior doctors recruited were those the clinical supervisor thought were most likely to 
agree to participate. The other prescribers and nurses were recruited according to their 
availability. 
Convenience sampling was also used for case note review. Clinic visits by the investigator 
were fixed and therefore reviews were of patients attending the clinic on these fixed days. 
Patients who fitted the following inclusion criteria were included: 
- Liver transplanted patients: CMV-negative recipient who received an organ from a 
CMV-positive donor or a re-transplanted patient. 
Kidney/SKP transplanted patients: All transplant recipients except cases where both 
the recipient and the donor were CMV-negative.  
- Valganciclovir indicated for CMV prophylaxis. 
- Database recorded incidents reported were analysed for the calendar year 2010. The 
self-assessment questionnaire was distributed to a convenience sample of staff. 
 
2.3.4 Ethics approval 
Approval to conduct the study was sought from the multidisciplinary transplant team and 
senior Pharmacy managers through submission to both the Pharmacy and Transplant Quality 
Improvement teams. Confirmation that the project does not require research ethics approval 
was confirmed from the scientific officer of the South-East Scotland Research Ethics 





3.1 Establish current practice in the use of valganciclovir 
Mapping the actual process for prescribing, administrating and monitoring the prophylaxis 
treatment with valganciclovir was done by conducting interviews with nurses and prescribing 
staff at the transplant ward at RIE. Prescribing staff with different grades of experience in 
both renal and liver were included. The investigator held a short power-point presentation to 
make the prescribers at the transplant ward aware of the project. The clinical pharmacist 
reserved a slot for the presentation in a regular meeting the prescribers attended. Staff 
participants were recruited by the clinical pharmacists at the liver transplant unit. E-mails 
were sent out to 5 of the healthcare professionals following verbal agreement, to arrange time 
and place for the interview for mapping the process and an interview for the student project 
running simultaneously. The chosen staff had verbally agreed to participate prior to the e-mail 
was followed up. The interview questions together with the protocol for the project were 
attached in the e-mail. One of the emailed prescribers did not answer nor participate in the 
interviews. Time and place for two of the prescribers was arranged through the clinical 
pharmacists for the renal transplant unit. One of the healthcare professionals who received an 
email was a charge nurse who arranged for two nurses to participate in the interview, one 
junior and one senior nurse. The interviews were conducted in quiet places around the ward or 
in the staff offices. Seven of the eight interviews were scheduled in one week, and one or two 
interviews were done daily. The last interview was agreed orally between the clinical 
pharmacist for the liver unit and the person being interviewed. Present at the interviews was 
the investigator, fellow investigator KP and the person being interviewed. KP had her own 
interview which was conducted before this interview. The interviews were tape recorded, and 
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the tapes were transcribed verbatim. A sample of 10 % of the transcript was checked by KP, 
before the tapes were destroyed to maintain anonymity in accordance with data protection act. 
1The questions for the interviews were prepared in advance. There was one set of questions 
for nurses on administration, and one set of questions about prescribing and monitoring for 
prescribing staff. (Appendix 3) 
 
3.2 Valganciclovir prophylaxis guidelines 
Pharmacy and medical staff confirmed that the guidelines used on the transplant unit at RIE 
were their own protocols. Both the liver transplant unit and the renal transplant unit have their 
own protocol. 
The renal unit guidelines were found by searching on their homepage (www.edren.org) with 
the search term “CMV”. The protocols for the liver transplant unit were obtained from 
clinical supervisor KD.  
 
3.3 Characterise the harm assessment based on data from audit 
 3.3.1 Reported adverse drug events   
An e-mail was sent to the quality assurance pharmacist to agree on how to obtain medication 
incident reports recorded on the database for the transplant unit for the time period of 2010. 
The investigator received a printed copy. The reports were carefully studied, mainly seeking 
for reports associated with valganciclovir. The investigator also looked for general errors that 
could possibly affect this treatment. This could for example be missed doses or administration 
of wrong drug. 
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 3.3.2 Clinical data from out-patient clinics 
The investigator together with a clinical pharmacist visited the out-patient clinic three 
different days to collect data. Two of those days renal/pancreas transplanted patient visited the 
clinic and the third day liver transplanted patients had appointments. A list of patients with 
appointments that day was collected from the clinic desk each of the three days. Patient 
information such as weight, sex and time since transplantation together with given doses of 
valganciclovir and communication with GP was collected from their files in the clinic. Date 
of birth and initials was also collected to allow data be retrieved from a data programme that 
had laboratory values. The patient’s initials and date of birth were removed before 
investigator left the hospital that day. The patient’s creatinine levels and frequency of 
laboratory monitoring was found through a clinical information computer system. The 
creatinine clearance was calculated using the Cockcroft-Gault equation, and the appropriate 
dose recorded. If the appropriate dose did not match the given prescribed, the clinical 
pharmacist assessed the patients’ clinical picture for reasons to justify the dose prescribed. All 
the data was filled out in a form made in advance. (appendix 6)  
 
3.4 Clinical staff opinions of where there is risk in the process  
A questionnaire for staff opinion on risk was developed and reviewed by the project team 
(Appendix 2). The questionnaire was handed to doctors and nurses at the same time as the 
interview for mapping the process. The questionnaires were also handed out to two clinical 
pharmacists at the ward, and one of the clinical pharmacists also handed it out to a transplant 
coordinator. The questionnaire had listed the whole processes of prescribing, administrating 
and monitoring in steps. At each step the staff could choose between four categories that they 
thought described the risk best: 
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- I think there is a risk of errors that will always lead to harm 
- I think there is a risk of errors  that might lead to harm in some cases 
- I think there is a risk of errors that will never lead to harm 
- I think there is no risk of errors (with or without harm as consequence) 
 
There was also a column were they could write in comments. The information given with the 
questionnaire was that this was to get the staff to assess the risk of harm in each step of the 
process.  
 
3.5 Pharmaceutical Care Issues  
A checklist for the pharmacist to fill out when they made interventions regarding patients on 
valganciclovir was developed (Appendix 3). Main care issue for the checklist was appropriate 
dose adjustment of valganciclovir. Two clinical pharmacists at the transplant ward filled out 
this checklist from the 14
th
 of February until the 11
th
 of April whenever they made 
interventions relevant for the checklist. There is one clinical pharmacist for the liver 
transplant unit, and one for the renal transplant unit. 
 
3.6 Opportunities for Quality Improvement 
With lack of time being an important issue, the project team decided that the project findings 
and opportunities for quality improvement were going to be discussed at a meeting with only 








4.1 Current practice in the use of valganciclovir 
The interviews with staff helped the investigator map the processes of prescribing, monitoring 
and administration. 
4.1.1 The process of prescribing 
The patient criteria for prophylaxis treatment are for liver transplanted patients either that the 
recipient is CMV-negative and receive a CMV-positive organ, or that a patient is re-
transplanted. For kidney/pancreas transplant patients the criteria are that either the recipient is 
CMV-positive before the transplantation or the donor is CMV-positive. In other words, the 
only ones that do not match the criteria and are not routinely put on valganciclovir 
prophylaxis are cases where both the donor and the recipient are CMV-negative. All the 
prescribing staff agreed on these criteria.  
The renal prescribers all agreed that the treatment should be initiated right after the 
transplantation. Among the liver transplant prescribers there was some uncertainty and 
disagreement. One of the senior doctors said that it should be written up on one of the two 
first days, but that it didn’t have to be started immediately after transplantation. A possible 
reason for the prophylaxis treatment to not be initiated immediately after is because the 
patient might be in intensive care. Another senior said it should be initiated at day seven, and 
the junior did not know and guessed the day after.  
For kidney transplanted patients the treatment duration is 180/200 days. For liver transplanted 
patients the duration is 90/100 days. Most of the prescribers agreed on the duration, except the 
two junior doctors who did not know. One of them guessed lifelong treatment. 
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All prescribers except the renal junior agreed that they decide the dose according to creatinine 
clearance, which all agreed is calculated by the Cockcroft-Gault equation. The renal junior 
said he/she used estimated glomerular filtration rate (eGFR) for deciding the dose. Although 
almost all of them know that the dose should be based on Cockcroft-Gault several of them 
admitted they do not calculate the dose themselves, but depend on the pharmacist to do it for 
them. 
None of the doctors considered any other factors than the kidney function when deciding the 
initiating dose. The senior renal doctor could share that none of their transplanted patients had 
normal kidney function so the doses for all their patients is based only on Cockcroft-Gault 
CrCl at initiating the treatment. 
Only the middle grade doctor had actually used the oral solution, all the others said they used 
tablets; the senior doctors added that they were aware that there is a oral solution available for 
patients with difficulties in swallowing or for patients with renal function less than 10 ml/min.  
4.1.2 The process of monitoring 
For monitoring the therapy several laboratory tests are taken when the patient is visiting the 
clinic. The patient can have a CMV-PCR (numbers of copies of CMV per millilitre blood) 
done, but they are not routinely done on patients on CMV prophylaxis unless they have 
symptoms. One of the senior doctors said he/she would check CMV-PCR after stopping 
prophylaxis for the two next visits, because that is often when they see CMV-disease develop. 
They also tend to do CMV testing in patients who are not on prophylaxis who have an 
unknown illness or unexplained changes in their liver function tests. Another important test is 
creatinine value so that the CrCl can be calculated. Full blood count and other monitoring of 
liver function are checked routinely post transplant anyway. 
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All the prescribing staff agreed that frequency of the laboratory tests monitoring varies with 
individual patients. The patients are not brought back for CMV monitoring alone, but it 
depends on their clinical picture. There was some uncertainty among the interviewees about if 
frequency should be changed after dose alteration among one junior and one senior doctor. 
Another senior doctor explained that when adjusting doses there are two possible situations 
for the patients. One of the situations is that the patient who has had renal dysfunction which 
has improved and the dose has been increased. The patient has become better and the periods 
between monitoring tend to be extended. The other possible situation is those who have 
progressed renal dysfunction who will be coming back more frequently as their kidneys 
appear to get worse. The frequency of monitoring will go up, but that is because of the 
complete clinical picture and not for valganciclovir monitoring alone.  
The senior doctors adjust the dose after CrCl based on the Cockcroft-Gault, although two out 
of three do not calculate it themselves. Some prescribers mentioned that they have big posters 
in the OPD (Out-patient department). The poster is made by the company Roche which 
manufactures valganciclovir. The middle grade doctor uses edren.org and the junior doctors 
adjust the dose using different types of literature. One of them uses their local protocol. The 
senior doctors were asked if they would change the dose according to blood tests at one 
occasion, or if they would wait to see if there is a trend. One prescriber answered that he/she 
personally thinks one should wait and see if there is a trend. The second one answered that 
he/she tends to adjust the dose after the level that they are at, but added that you would 
usually have seen a trend before the patient reached another dose level. The third senior 
prescriber said that it depends. In some occasions the doctor sees a patient who is right on the 
edge of moving into the next group and the patient will not come back for the next couple of 
weeks. It is easier for the patient to get it sorted out then and there. The laboratory results are 
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taken right before the doctor’s appointment at the clinic and will not come back before that 
evening, so sometimes the prescriber predict that the CrCl will push the patient into the next 
dose level and changes the dose. Then at evening, when the results come back, the doctor will 
phone the patient and tell him/her to stick to the dose he/she was on, if the creatinine 
clearance was not as predicted. 
All the doctors said that they communicate with GPs, but that they do not expect them to 
participate in the monitoring. The patients visit the clinic so often that getting the GPs to do 
additionally tests would only complicate things. One consultant said that they may ask 
patients to attend their practise to have full blood count and renal function checked, but the 
hospital get the results and make the decisions. So the GPs are involved as far as participating 
with taking blood tests, but they don’t expect the GPs to make important decisions regarding 
valganciclovir or other transplant medications. This communication is documented in letters. 
4.1.3 Prescribing and monitoring 
One senior doctor said they use the unit protocol which is reviewed every year. Another 
senior doctor said they use the guidelines from The British Transplant Society. The third 
senior prescriber said they used guidelines based on Cockcroft-Gault. The middle grade 
doctor answered that he/she uses www.edren.org.  The renal junior said he/she does what the 
pharmacist tells him/her what to do most of the time, and the liver junior did not know.  
The middle grade doctor said he/she follow the guidelines accurately, while the senior doctor 
said that they are guidelines not rules and that he/she deviates, and the reason for that was past 
experience. 
The prescribers were asked what they do and how they would document it if they discovered 
a prescribing-error or instances where the treatment is not optimised. One of the senior 
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doctors only answered on how he/she would document it which was only in written letters. 
All the other doctors answered that they would correct the error. One senior doctor said he/she 
would document it in letters. And that they would not discuss it at a m&m-meeting (morbidity 
and mortality meeting). Another senior prescriber used adjusting the valganciclovir dose as an 
example. The doctor does not think of it as a prescribing error if someone has failed to 
recognise the improving function and make a change. The doctor would not record that sort of 
incident on the database, because the prescriber thought the database would just get 
overloaded with those kind of reports, because there are too many examples of that. The 
middle grade doctor would document accurately what had happened, and what he/she is going 
to do about it. He/She would also communicate either verbally or in writing depending on the 
urgency on the situation with the relevant people involved. The aim would be to correct it for 
that patient and minimizing the likelihood of a similar error happening to other patients. One 
junior doctor said he/she would write in the notes what had happened and if there was any 
harm to the patient he/she would tell the patient at the same time, so he/she was informed that 
there has been an error. Also he/she would make sure that all the doctors looking after the 
patient knew and the consultant was aware. The other junior prescriber said he/she suppose 
he/she should fill out an incident report about it, because there had been an error. He/She said 
you should let the senior doctors know, and also the nurse because he/she thought they had 
their own incident reports to fill out. 
4.1.4 The process of administrating 
Both of the nurses stated that the doctors are very good at letting the nurses know about new 
prescriptions, and they estimated that 99 percent of the time they remember to tell them if 
there is a new drug prescribed for a patient. Ordering for ward stock from pharmacy happens 
routinely twice a week by trained nurses. This is documented on the pharmacy sheet where 
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the orders are written. The ordering for individual patients is done by trained nurses or a 
pharmacist.  
On a question on how the drug rounds happens the senior nurse answers that they now use the 
POD-system (patient’s own drugs) where the patient has their medication locked in a bedside  
locker. He/She said they had an old system were they had a big drug trolley (that contained 
stock drugs) that made people aware that the nurses are on drug rounds so they would not be 
disturbed. The nurse is less excited about the new system where he/she can use 90 minutes on 
six patients compared to the old system were it took her/him one hour to give drugs to the 
whole ward. The new administration system has come with a few risks, especially since 
people may not realise that the nurses is on drug rounds. Both of the nurses were positive to 
the new implementation of tabard that says:”Do not disturb, Nurse on drug round”.  
The nurses were asked if they are aware of the precautions required for handling 
valganciclovir. The senior nurse did not, but the junior nurse was aware that gloves should be 
used when handling this medicine and that you should not come into contact with it, and the 
gloves have to be put in a special bin after they are used because of its toxicity. He/She says 
that both the nurses and the pharmacists give this information to the patients. 
If there is an administration error both nurses agree that the doctors will have to be notified. 
The senior nurse says that in 9 out of 10 times this will be discussed with the patient, and that 
it has to be documented. The junior nurse stated that an incident report has to be filled out on 





The renal/pancreas team at the Royal Infirmary follows their own protocol for CMV 
prophylaxis treatment. The guidelines are found on their homepage www.edren.org, and the 
homepage states it was last reviewed December 2009.  The patient criteria for CMV 
prophylaxis are that all patients except CMV-negative recipient with a CMV-negative donor 
should be treated. The drug of choice is valganciclovir. The treatment is to be initiated within 
10 days of transplantation, and continues until 180 days post-transplantation.  The dose is 
adjusted according to creatinine clearance (calculated with Cockcroft-Gault equation) which 
is a measure for kidney function. This is shown in table 3: 
Table 3: Dose adjusted after creatinine clearance in guidelines [61] 
CrCl (ml/min) 
Valganciclovir dose for 
prophylaxis against CMV disease 
 ≥ 60 900 mg (2 tablets) once daily 
40 – 59 450 mg (1 tablet) once daily 
25 – 39 450 mg (1 tablet) every 2 days 
10 – 24 450 mg (1 tablet) twice a week 
 < 10 
100mg three times weekly after 
dialysis (liquid formulation) 
 
Valganciclovir is available in tablets (450 mg) and as an oral solution. The tablets should be 
administrated with food, and not crushed.  
The guidelines also state that full blood count and liver function tests must be monitored 
daily. A common reason for discontinuing the treatment before the 180 days is over is 
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leucopenia, which can occur due to treatment with valganciclovir. Post transplant patients are 
not routinely tested for CMV, but in cases of any illness where CMV is suspected, tests 
should be run. The handbook suggest CMV PCR, and mentions also that respiratory or other 
samples can be sent to virology [61] 
When searching for CMV within edren.org, one of the search results found was the immuno 
suppression handbook with a paragraph on CMV prophylaxis. One of the things mentioned 
was that valganciclovir dosing was according to eGFR. [62]  
The liver transplant unit at RIE has their own protocol they follow which are reviewed yearly. 
The protocol says that high risk recipients with normal kidney function will receive 
valganciclovir 900 mg daily starting at day 7 after transplantation and continuing until 3 
months after transplantation. The dose needs to be adjusted in renal impaired patients. High 
risk recipients are defined as either CMV-negative recipients who receive a CMV-positive 
graft or re-transplants.[37]  
 
4.3 Harm assessment based on real data 
4.3.1 Collecting data from incident reporting system  
In 2010 the transplant ward at RIE had 34 incidents reported in Datix®. Of these reports only 
one has specified that it concerned Valganciclovir, but 4 of the reports about drug errors had 
not mentioned which drug the incident concerned. The one report on Valganciclovir was 
about a missed dose and the seriousness graded as low. This was discovered by medical staff 
and the patient. The dose was missed due to staff attending a cardiac arrest on another patient. 
Pharmacist and senior staff were informed.  
42 
 
Three of the four reports which had not mentioned which drug the incidents concerned were 
in the category of drug not signed for at administration.  
Out of the 34 reports, 13 of them concerned missed doses and 5 of them not signing for 
administration of drugs. It appears in the reports that it can be difficult to choose how to 
categorise these two because they do not know if the dose is not given or if it is just not 
signed for. There were also a couple of reports where medication not given yet were already 
signed for. 
21 reports on administration errors, 4 reports on prescribing errors, 4 report on other, 3 on 
medicine, 1 report on information and 1 not categorized.  
4.3.2 Look at real data from a snapshot in the clinic 
On the first day of renal clinic 2 out of 12 patients with appointments fitted the inclusion 
criteria (see 2.3.3). On the second day 1 out of 11 fitted the criteria, and for day 3 only 1 out 
of 17 were included. The communication with GP for patient 1 was exceptional and the 
clinical files were updated with the letter sent to GP only 4 days earlier. The clinical files for 
the rest of the patients contained many letters to the GP and the clinical pharmacist considered 
the communication with the GP good. The results from the out-patient clinic is summarised in 





























This patient have 
been diagnosed 
with CMV viremia, 




the dose as 
appropriate 






2-3 times a 
week 
--- 







CrCl was 61.8, and 
has barely crossed 
the border between 
450 and 900 mg 
daily 





feb.11 Weekly --- 
 
4.4 Harm assessment from staffs opinion 
Table 5 summarizes the opinions of the participating staff on the risk of harm through the 
whole treatment process for SOT patient. 
Table 5: Staffs opinion on risk of harm 
 
I think there is a 
risk of errors that 
will always lead to 
harm 
I think there is 
a risk of errors  
that might lead 
to harm in 
some cases 
I think there is a risk of 
errors that will never 
lead to harm 
I think there is 
no risk of 





Deciding if Valganciclovir should be 
prescribed 1(nurse) 10 
   Deciding when to start treatment 1(nurse) 9 1 (pharmacist)  
 Deciding dose for patients with 





coordinator) 1= Not applicable 




   
Calculating Creatinine clearance 
2(junior doctor 
and nurse) 9 
  
1= Cockcroft-Gault depends 
on ideal body weight 
Choosing correct drug formulation 1(nurse) 8 
2 (pharmacist, senior 
doctor) 
  
Deciding treatment duration 1(nurse) 9 
1 (pharmacist, senior 
doctor ) 
  
      
Administering right drug 1(nurse) 10 
   
Administering at right time 
 
10 1 (senior doctor) 
  
      Adjusting dose after measurement 
of Creatinine clearance 1(nurse) 10 








4.5 Pharmacist Checklist  
The pharmacist on the liver transplant unit made 2 interventions regarding the CMV 
treatment.  One of the interventions made was advising to decrease a dose. The other 
intervention was about initiating valganciclovir prophylaxis. A patient who himself was 
CMV-negative, received a graft from a CMV positive patient had not been prescribed CMV 
prophylaxis 9 days after the transplantation. The clinical pharmacist for the kidney transplant 
team made 13 interventions on 8 different patients regarding the CMV treatment. One patient 
had valganciclovir written up in their chart, although both he himself and his organ donor 
were CMV negative. The pharmacist noted this the first day after transplantation.  The 
pharmacist advised to increase the dose 11 times on 6 different patients, and reduce the dose 
one time on one patient.  
 
4.6 Presenting findings 
The results from the project were discussed at a project team meeting and the team agreed that 
the main finding was that adjusting doses according to CrCl seems to be a problem and action 











5.1 Current practice in the use of valganciclovir 
As it emerged in the interviews, not all nurses are aware of the precautions for handling 
valganciclovir. This drug is as mentioned in the introduction (see 1.4.4) considered potentially 
carcinogenic and teratogenic, and staff should avoid direct contact with broken or crushed 
tablets. The lack of knowledge this nurse had about handling medication might not have led to 
harm, but it is definitely a risk for the nurse. However, with only two nurses included in the 
project, it cannot be concluded if this is a general problem at the ward. 
It also emerged that there are some gaps of knowledge regarding CMV prophylaxis treatment, 
especially among the junior doctors. The knowledge about this treatment could be improved 
if either a pharmacist or a senior prescriber routinely held lectures regarding this subject 
mainly for junior doctors and nurses. 
The prescribers do not seem to separate between renal prophylaxis treatment for 200 days and 
180 days, or liver prophylaxis 100 days and 90 days. The guidelines say 90 days for liver and 
180 days for renal. This was discussed between the investigator and the clinical pharmacist, 
the clinical pharmacist stated that in practice the treatment is not stopped after exactly 90 or 
180 days.  Literature is done on all of the above mentioned timeframes (90, 100, 180 and 200 
days).[25, 26]  
Although not initially thought of when developing the questions, the investigator considered 
it important to know whether the prescribing doctor waited for a trend before adjusting the 
doses. Therefore this question was added after the interviews with one junior and one middle 
grade doctor. The other junior answered that he/she was not in the clinic, so he/she was not 
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asked this question. It could have been of further interest to have asked the junior/middle 
grade doctors if they had been taught anything about this from the seniors or if they had 
opinions on how this should ideally be handled.   
The senior prescribers seemed to agree that a trend should be seen before adjusting the dose. 
One consultant said he/she tends to adjust the dose after the level they were at, but that they 
usually have seen a trend before the patient reach a new dose level. Although this consultant 
expressed him/her self a little different than the others, the investigator interprets his/her 
answers as he/she agree with the other consultants. 
One consultant said that he/she initially predicted the dose and adjust the dose after that, then 
later he/she change it according to the patients actually CrCl when the laboratory tests come 
back, and then phone the patient to let change the dose back if he/she had predicted the dose 
wrong earlier. That might be a good way of doing it. Another possibility is that the patient 
can have his blood tests taken to the GP a few days before their appointment at the clinic. 
However this arrangement will most likely will not be relevant for patients seen on a weekly 
basis or more frequently. As the local project showed the titration of dose for this drug is a 
problem, so measures to improve this treatment better need to be initiated. One idea is that a 
prompt could be included in the out-patient proforma document as a reminder in case the 
patient is seen by different prescribers each clinic appointment.  
 
An important weakness for this method is the selection of interviewees. The senior doctors 
chosen were those the pharmacist thought it was most likely to agree to participate. The staff 
considered likely to participate were staff considered positive towards the project and might 
therefore had opinions on the project matter that they would like to get across. The opinions 
might have been different with other prescribers. On the other hand were the prescribers who 
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wanted to participate were very honest, this might not have been the case if prescribers with 
a negative attitude towards the project had been interviewed. They might not have given as 
honest answers.  
 
5.2 Guidelines 
Although the project has a small sample size, the interviews indicate that the renal junior and 
middle grade prescribers use their protocol and the clinical pharmacist relatively frequently. 
This became apparent as it was their answers to several of the questions. That implies that it is 
crucial that the protocols are accurate, easy to understand and leave little room for 
interpretation. In one part of the renal unit handbook for immuno suppression it is stated that 
valganciclovir should be adjusted according to eGFR. That might be the reason that the renal 
junior doctor answered this on how to adjusts valganciclovir dosage. At RIE eGFR is 
calculated by the modification of diet in renal disease (MDRD) equation. A retrospective, 
cohort-controlled study compared the use of MDRD versus Cockcroft-Gault equation for 
renal dosing adjustments in patient with chronic kidney disease. It emerged that there was a 
significant variability between using MDRD and Cockcroft-Gault.[63]  Using eGFR value 
may not always lead to harm, but it can be a risk. The renal immuno suppression protocol 
should therefore be reviewed. 
The protocol for the liver unit is quite straightforward and easy to understand. The protocol 
states that the valganciclovir dose should be adjusted according to kidney function. It does 
however not say how to adjust it or what kidney function test it is dependent on. This might 
be self explanatory for most prescribers, and they might say they know where to find it if they 
do not have it in their head. For junior prescribers who perhaps use the protocol more often, it 
might have been good to have included both the equation and a table with recommended 
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doses under CMV prophylaxis in the protocol. A concern was that the liver junior doctor 
answered that he/she did not know what protocol to use. It was not clear if the doctor just 
could not remember what guidelines to use at the moment, or if he/she was not aware of the 
local protocols. It is crucial that the staff is aware of the guidelines, and one way to 
accomplish this could be to make them available online.  
 
The renal protocol is quite easy to understand and contains a lot of useful information. Unlike 
the liver protocol, they have included a table over recommended doses depending on CrCl. It 
does not state that CrCl should be calculated by Cockcroft-Gault, but this was something all 
the prescribers knew in the interviews, which indicate that this is well known among doctors. 
Four out of six prescribers said they get the pharmacist to calculate the dose for them, or 
answered that they do what the pharmacist tells them to when adjusting the dose. One doctor 
used the edren.org calculator. One thing that would be interesting to find out is why only one 
out of six prescribers calculate the CrCl themselves? The investigator suspects it might be 
difficult to find the Cockcroft-Gault equation from a reliable source, as he/she could not find 
the equation in the protocol for the renal unit, under CMV prophylaxis in the liver unit 
protocol, or in the SPC[32] 
The kidney unit protocol does include the table with dose recommendations according to 
CrCl, but a more detailed protocol for both renal and liver might have improved the CMV 
prophylaxis treatment.  
The renal protocol also states that full blood count and liver function tests must be monitored 
daily, this seems impractical for out-patients and the investigators suspects that this 
information is incorrect. Through the interviews it emerged that the patients do not visit the 
clinic more often than twice a week. The information might be intended for in-patients or 
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patients receiving treatment of CMV infection, but that should have been specified. Following 
this study it is suggested that the renal protocol be reviewed. 
 
5.3 Harm assessment based on real data 
5.3.1 Collecting data from incident reporting system  
Datix® is very subjective. In the report of missing a valganciclovir dose the incident was 
graded as low, another incident with missing a dose of another drug was graded as medium. If 
these reports are done to prevent a similar episode from happening again, then the error of the 
incident should be graded on the seriousness of the error and be the same grade, and not based 
on the possible outcome.  
If the incident is graded on the patient’s possible outcomes then the whole clinical picture for 
the patient should be explained in detail. This leads on to another limitation, the incident 
reports varied a lot in length of description and amount of details included. Some reports were 
one sentence, while others were considerable longer. This may be a result of lack of training 
(capability) or perhaps lack of time (capacity). It is important that the staff are properly 
trained in how to report incidents and aware of the importance of prioritising this activity. It 
has to be clear to the health care professions when they should fill out an incident report, what 
and how to fill it in, and how to grade the seriousness of the incidents. 
As it emerged in the results, most of the reported incidents concerned drug administration. It 
is therefore important to come up with initiatives to prevent administration errors.  The nurses 
interviewed in mapping the process could also support these findings, and expressed their 
concern with the constant interruption of nurses on drug rounds.  
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This might indicate that only administration errors are occurring, however this is not very 
likely. We may therefore assume that the nurses are better at reporting incidents. The reasons 
that other health care professions is not reporting might be lack of time, fear of being blamed 
and personal opinion that it is a waste of time.  
One interesting finding was that the Datix® reports do not include any reports on up titration 
of valganciclovir as the renal function increases. One of the senior doctor said there are so 
many examples of prescribers failing to recognize that the dose should be increased that 
Datix® would be full of these kinds of reports. Also the pharmacist interventions where 11 of 
15 interventions made were up titration suggest that this is a problem. Reason to why they are 
not reported may be as the senior prescriber does not regard this as a prescribing error. 
Another possibility might be that they just do not report incidents in Datix®. If the incident 
reports were used by practitioners themselves as a learning tool and were seen to be useful, 
perhaps they would be used more often. 
5.3.2 Look at real data from a snapshot in the clinic 
This method was meant to actually prove if there are problems regarding adjusting 
valganciclovir dose according to creatinine clearance, but the sample size of patients meeting 
the criteria and being checked became much smaller than anticipated. By only looking at four 
patients it is impossible to conclude with anything, but after visiting the clinic three times 
time did not allow to collect more data in this project.  
A future project could be to investigate this with a larger sample size. A strength with this 
method was that the investigator had a clinical senior pharmacist to help assess each case. 
Some patients had complications and could not be treated using the standard protocol.  
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Unlike prescribing and monitoring this treatment for in-patients have different kinds of staff 
as a checkpoint, monitoring the therapy for out-patients have no checkpoint. Maybe it could 
have been possible for the pharmacist to check medications in out-patients, especially patient 
on valganciclovir. 
 
5.4 Harm assessment from staffs opinion 
What the results of this questionnaire do tell, is that most staff thinks there is a risk of harm in 
all the steps in the process. Although most staff have answered that they think there is a risk 
of harm in some cases, in most of the steps, it is interesting that juniors and nurses are the 
only ones who have graded something as “I think there is a risk of errors that will always 
lead to harm” and only consultants, coordinators and pharmacist has graded things as “I 
think there is a risk of errors that will never lead to harm” and “I think there is no risk 
of errors (with or without harm as consequence)”.  
The questionnaire might have been interpreted in different ways. The staff might have thought 
the questionnaire meant that they should assess the risk of an error to actually reach the 
patient without anyone picking it up. Or they might have though the questionnaire meant that 
they should assess the risk of their error leading to harm if it affected the patient.  
The outcome might have been better with an interview, the original idea was to ask the staff 
open questions and let them talk about where they think the risk lay, but time did not allow 
for this to be done. Conducting interviews are time consuming and instead of having two 
different interviews in this project, it was decided to use a questionnaire to assess the risk. The 
questionnaire was developed so that staff had to assess the risk of the whole process, also 
steps they do not take part in themselves, to see if they had opinions about other health care 
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professionals work. The plan was that the comment column would be what gave most 
information from the questionnaire. The investigator thought the staff would state why they 
checked off as they did, but only two comments were added in one questionnaire out of the 11 
that were filled out. The column should not have been called “comments”, but something to 
get the staff to explain why they crossed off as they did. Another alternative was that the 
investigator could have given more information about the questionnaire before handing it out. 
It should have emerged that the aim of this questionnaire was to find out in which steps staff 
think there is a risk of harm, and why.   
 
5.5 Pharmacist Checklist  
The pharmacist interventions indicate that adjusting the doses according to changing CrCl is a 
problem. This does not necessarily lead to harm for the patient. These interventions are done 
frequently by the pharmacist and they are in a way a checkpoint to ensure safe medicine use 
for in-patients. Maybe it could be an idea to use the pharmacist as a checkpoint for out-
patients as well.  
A weakness about this method was that the checklist could have been better. It should have 
included the categories: not prescribed when should have been, and prescribed when should 
not have been. Also the checklist had space for all the needed information to calculate the 
creatinine clearance, but not the actually given dose. So if the investigator wants to have the 
information available, all the information should be collected. 
Strengths for this method are that the checklist was short and user friendly, which increases 
the chance of it actually being used. One of the clinical pharmacist who used it was included 
in the development of the checklist. Only two clinical pharmacists have been used to record 
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interventions which increases the chance of it being accurately filled out, compared to if many 
people would have filled it out.  
To check if the implementing suggestions have an effect, the Plan-Do-Study-Act cycle could 
be used. Using this cycle, this project would be the planning, implementing the improvement 
suggestions would be doing. The study step could be to see if the number of interventions 
would decrease if the pharmacists recorded interventions for a new period of two months. 
Another measure of improvement could be to conduct new interviews with junior doctors to 
















The aim of this thesis was to evaluate the processes of prescribing, administrating and 
monitoring the prophylaxis treatment with valganciclovir, and one of the objectives/methods 
was to make suggestions for improvement.   
Several opportunities for improvement emerged through this study. The local protocols are 
one of them where information should be reviewed to provide accurate detail. Previous work 
showed that the valganciclovir dose is not always adjusted to CrCl, and that this seems to 
increase the incidence of CMV disease. The pharmacist interventions and the interviews with 
prescribers in this project support these findings. It also emerged that there were gaps of 
knowledge regarding this treatment, especially in junior doctors, and that almost none of the 
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Interview; Mapping the process of prescribing and monitoring the treatment of 




What are the patient criteria for starting Valganciclovir prophylaxis (in transplant patients?)?  
 
When during the transplant process is the treatment initiated? 
 
 
Does every patient with normal kidney function get the same dose, or do other factors 
influence dose adjustments?   
 
- If other factors are considered, are prescribers supported through some form of 




How do you decide the dose for a person with renal impairment? 
 
 
Which formula do you use to calculate Creatinine clearance? 
 
 
Do you use eGFR for informing your prescribing decisions? 
 
Do you ever use valganciclovir oral solution? 
- If yes, in which cases? 
 
 








When monitoring: Which lab tests are done and how often?  
- Does the frequency of monitoring change after adjusting doses? 
 
How do you adjust the dose according to Creatinine clearance in renal impaired patients? 
(When do you decide to lower the dose and by how much?) 
-   Do you use literature such as for example BNF or guidelines, or do you just use     
your memory? 
 
Do you follow any guidelines? 
-  if so which one and do you follow accurately or do you deviate?  
- Do you have specific reasons for this? 
 
Do you communicate with the GP and expect them to participate in monitoring this therapy? 
- How is this communication documented? 
 
If you identify a prescribing-error or instances where the treatment is not optimised, what do 












Interview; Mapping the process of administrating Valganciclovir after interviewing 
nurses. 
 
How are nurses made aware of new prescriptions? Is the nurse notified? Or do they have to 
check the kardex? 
 
Are all pharmacy orders from nurses?  
- If no, who does it? 
 
- How are the orders documented at the ward? 
 
What is the process of drug administration ?   
- Are any measures initiated to improve medicine safety in administration?   
 
Are you aware of the precautions required for handling this medicine (valganciclovir)? 
 



































Mapping the process of prescribing and monitoring the treatment of Valganciclovir, 
after interviewing prescribing staff. 
 
Interview with liver senior doctor: 
 
Prescribing: 
What are the patient criteria for starting Valganciclovir prophylaxis (in transplant 
patients)?  
We have two different criteria, one for liver and one for kidney/pancreas. The criteria for the 
liver side are CMV-positive to CMV-negative recipient or in re-transplants. 
For renal/pancreas: anyone who is either donor (CMV)-positive and recipient (CMV)-
negative or recipient positive regardless of donor-status. So it’s slightly wider.  
 
When during the transplant process is the Valganciclovir treatment initiated? 
It is written up immediately after transplantation, they might not get it immediately after 
because they might be in intensive care and they are not providing oral medicines. It doesn’t 
need to be gives the 2 first days, but it is written up on the first, or should be written up on the 






Does every patient with normal kidney function get the same dose, or do other factors 
influence dose adjustments?   
It is on the Cockcroft-Gault, so it should be renal function. We have changed dose depending 
on marrow suppression, but that is not at the time of initial prescription. 
 
 
- If other factors are considered, are prescribers supported through some form of 
guidelines or is it entirely independent clinical judgement?  
At the time of prescription It is solely based on Cockcroft-Gault. I don’t remember us 
modifying anyone right at the outset. We have further down the line, but at the initial 
prescription it’s the Cockcroft-Gault. Whether we get it right is a different matter. 
 
How do you decide the dose for a person with renal impairment? 
(This question was not asked because it was already answered) 
Which formula do you use to calculate Creatinine clearance? 
(This question was not asked because it was already answered) 
 
Do you use eGFR for informing your prescribing decisions on Valganciclovir? 
No! I use the pharmacist (laughs) I e-mail her regularly for her to tell me the correct dose 
 
Do you ever use valganciclovir oral solution? 
- If yes, In which cases? The answer is I don’t know. I don’t know if any patients have 
been put on it. 
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What is the prophylaxis treatment duration?  
For liver: 3 months after transplant or an episode of acute rejection 
For kidney: 6 months 
 
Monitoring 
When monitoring: Which lab tests are done and how often?  
Urea Creatinine and full blood count are done when they come to clinic. How often depends 
on the clinical condition, and duration from transplant, Initially at least weekly, after a month 
it is down to forth nightly and by three months it is probably been three weeks. Since they’ve 
been seen. They are not brought back for CMV monitoring as such, but for clinical reasons. 
- Does the frequency of monitoring change after adjusting doses? 
 No, well usually for the liver side if we have adjusted the dose I suppose there are one 
in two conditions that have happened. One is that they have had renal dysfunction 
which has gotten better and therefore their prophylactic dose has been increased, in 
other words they are well. So therefore the periods between monitoring tends to be 
extended. 
And then there is the group who have progressed renal dysfunction post-transplant 
period who will be coming back ever more frequently as their kidneys appear to get 
worse. So their frequency of monitoring will automatically go up, but it is not for 




How do you adjust the dose in renal impaired patients?  
I email my transplant pharmacist and provide the information needed to work out the 
Cockcroft-Gault and then he/she tells me the answer. I don’t try to do it myself (laughs). 
 
- Would you change the dose if it wasn't optimal according to blood tests at one 
occasion? Or do you wait to see if there is a trend? 
 I would tend to adjust it after the level that they are at. The worrying being that when 
you see them in the clinic if they come in with a worsening renal function, then that is 
going to continue for a while. You are probably not going to see them for another 
week. To be honest there has usually been a trend anyway before. You have already 
seen a trend in the previous dose level, and then are moving to another dose level. So 
you probably already seen that trend. 
 
-  Do you use literature such as for example BNF or guidelines, or do you just use     
your memory when adjusting doses? 








In general, do you follow any guidelines when prescribing and monitoring 
Valganciclovir?  
The guidelines from The British Transplant Society. 
-  if so which one and do you follow accurately or do you deviate?  
(laughs)They are guidelines, they are not rules. They inform decisions. They are 
guidelines, they are not mandatory. We have had patients who are CMV-positive to 
negative transplant but have become profoundly leucopenic, and we have stopped 
Valganciclovir early. So that would not necessary be in the guidelines but done for 
clinical reasons. 
- Do you have specific reasons for this? 
(This question was not asked because it was already answered) 
 
Do you communicate with the GP and expect them to participate in monitoring this 
therapy? 
No, we don’t expect them to monitor themselves. Maybe ask patients to attend their practise 
to have full blood count and renal function checked, but we get the results and we make the 
decisions. So they are involved it is as far as participating with taking blood tests, but we 
don’t expect them to make important decisions.  
- How is this communication documented?  
In clinical letters, they probably will go out a while after they have had their blood test 
because of secretary delays. But the co-ordinators and the patients they all know. For 
most practises the GP (noise). 
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If you identify a prescribing-error or instances where the treatment is not optimised, 
what do you do, and  how and where do you document this?  
Correct the error, make sure they are on the right dose, right treatment, you correct what is 
wrong. It gets documented in letters. For the liver side to be honest we don’t discuss it at a 



















Interview with liver senior doctor 
 
Prescribing 
What are the patient criteria for starting Valganciclovir prophylaxis (in transplant 
patients)?  
We prescribe valganciclovir prophylaxis in two situations, one is a patient who receives a 
graft that is positive for CMV and they themselves are CMV-negative, so they will get a three 
months prophylaxis with valganciclovir. And all re-transplants gets valganciclovir, people 
who have had a liver transplant before and have a new transplant, not in the same episode. 
They should at least get valganciclovir for three months minimum. 
 
When during the transplant process is the Valganciclovir treatment initiated? 
The prophylaxis is started at day 7. 
 
Does every patient with normal kidney function get the same dose, or do other factors 
influence dose adjustments?   
I think they get the same dose if the kidneys are okay. They should get 900 mg  
 
- If other factors are considered, are prescribers supported through some form of 
guidelines or is it entirely independent clinical judgement? 






How do you decide the dose for a person with renal impairment? 
We usually speak to the pharmacist. we get this discussion because the company (Roche) who 
make Valganciclovir they always tell us that it is based on Cockcroft-Gault which is not what 
we use or eGFR for renal function. So that’s what their data is based on, So we depend a bit 
on the pharmacist to tell us what the Cockcroft-Gault give. Cause the number that we get up 
there is not Cockcroft-Gault. Estimation of eGFR. 
As far as I can remember if they got normal kidney-function it is greater than 60 ml/min then 
they get 900 mg. If it’s 40 -60 ml/min its 450 mg. And less than that then we have alternate 
things. So we do depend a bit on the pharmacist on help on that regard, but we are aware that 
if the kidneys aren’t working properly then we need to reduce the dose. I suspect we are 
reasonable at that, the problems that we have had is when the kidneys get better and we have 
not gone back up to the dose. We have had 1or 2 problems with CMV when we have not 
increased the dose appropriately. 
 
Which formula do you use to calculate Creatinine clearance? 
(This question was not asked because it was already answered) 
 
Do you use eGFR for informing your prescribing decisions on Valganciclovir? 






Do you ever use valganciclovir oral solution? 
- If yes, In which cases? 
Not to my knowledge. I am aware that it is there, but I haven’t used it yet.  
 
What is the treatment duration?  




When monitoring: Which lab tests are done and how often?  
CMV-DNA is what we ask for. How often probably varies from individual to individual. If 
they are in prophylaxis I certainly don’t do CMV-DNA unless they have symptoms. If they 
stop prophylaxis after three months I would for the two next visits do CMV-DNA. Cause that 
is often were we see CMV-disease, when they stop prophylaxis. And we tend to do CMV 
testing in patients who are not on prophylaxis who have an unknown illness or unexplained 
changes in their liver function tests around and after the first six weeks. I’m not sure if there is 
anything written down that tells us what we should do. 
 
- Does the frequency of monitoring change after adjusting doses? 





How do you adjust the dose in renal impaired patients?  
If CrCl reduces below 60 then we drop from 900 to 450 mg daily. And if it’s less than 40, 25-
40 it is 450 mg alternate days, and if it’s less than that I think it is twice a week. 
 
- Would you change the dose if it wasn't optimal according to blood tests at one 
occasion? Or do you wait to see if there is a trend?  
Personally I think you should wait and see if there is a trend 
-  Do you use literature such as for example BNF or guidelines, or do you just use     
your memory when adjusting doses?  
I usually use the pharmacist. There is a kind of poster that gives us the information 
from the company. I don’t often use the BNF.  
 
In general, Do you follow any guidelines when prescribing and monitoring 
Valganciclovir?  
The guidelines that we follow is our own protocol, which we discuss every year, and I am 
aware that the renal physician have changed their prophylaxis from three months to six on the 
basis of a recent study. We haven’t adopted that yet, and I am not aware of any liver 
transplant guidelines who have suggested we should. In my own opinion there are patients 
who I think we should be given six month prophylactic treatment. These are the younger 




- If so which one and do you follow accurately or do you deviate?  
I usually deviate  
- Do you have specific reasons for this?  
Well yes (laughs), from my own past experience. There have been patients were we 
stop after three months and they get CMV-disease and become quite unwell for a time. 
So there are patients were I have chosen to keep them on prophylaxis for a little bit 
longer than three months.  
 
Do you communicate with the GP and expect them to participate in monitoring this 
therapy? 
We do communicate with them, but don’t really expect them to participate in the monitoring 
because if you ask them to do CMV-DNA that never happens. So we don’t expect them to do 
viral-loads. We ask them on occasions to check kidney function and see if there has been any 
change. 
- How is this communication documented?  
Hopefully, (laughs) 
 
If you identify a prescribing-error or instances where the treatment is not optimised, 
what do you do, and  how and where do you document this? 
That’s a good question. If I was being honest, which I should I would only document it in a 
written letter within the notes. I wouldn’t do anything more. 
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Interview with liver junior doctor 
 
Prescribing 
What are the patient criteria for starting Valganciclovir prophylaxis (in transplant 
patients)?  
I think.. (pause) If it is a CMV-positive donor with a negative recipient, or the recipient is 
CMV-positive.   
 
When during the transplant process is the Valganciclovir treatment initiated? 
I don’t know (laughs). I have no idea. A day afterwards? I’m not entirely sure.. (pause) If with 
Valgan, that’s oral, so it as to be when they are kinda alert and awaken enough to take it, but I 
don’t know (laughs). 
 
Does every patient with normal kidney function get the same dose, or do other factors 
influence dose adjustments?   
Well I know Creatinine clearance comes in to it, but I’m not sure what else is involved in 
adjusting the dose.. weight maybe? (pause) Not sure. 
 
- If other factors are considered, are prescribers supported through some form of 
guidelines or is it entirely independent clinical judgement? 





How do you decide the dose for a person with renal impairment? 
You ask a pharmacist to work it out(laughs) I think it’s based on creatinine clearance, but I’m 
not entirely sure, and it its different if they are dialysed or on a filter. It’s a different dose 
regiment. 
 
Which formula do you use to calculate Creatinine clearance? 
It should be the Cockcroft-Gault formula for creatinine clearance, not the eGFR from the list 
 
Do you use eGFR for informing your prescribing decisions on Valganciclovir? 
No 
 
Do you ever use valganciclovir oral solution? 
- If yes, In which cases? 
I have never used it, it as always been the tablets. 
 
What is the treatment duration? 








When monitoring: Which lab tests are done and how often?  
I don’t know, I presume that they should be monitoring renal function and then dose adjust. 
And they need to keep an eye on the full blood count. I don’t know if it is as bad with 
valganciclovir as with for example foscarnet. I’m not entirely sure. I have no idea how often 
they do that. When they are in-patients they are done every day, but I don’t know what 
happens when they go home.  
 
- Does the frequency of monitoring change after adjusting doses? 
(This question was not asked because he/she already answered that she did not know 
the frequency) 
 
How do you adjust the dose in renal impaired patients?  
There is a little table that you use. It is on our wall in the doctors’ room. It tells you what to 
give. So I just look at that. 
 
- Would you change the dose if it wasn't optimal according to blood tests at one 
occasion? Or do you wait to see if there is a trend? 
(This question was not asked because he/she had said in the interview to the parallel 




-  Do you use literature such as for example BNF or guidelines, or do you just use     
your memory when adjusting doses? 
(This question was not asked because he/she had said in the interview to the parallel 
project conducted earlier that he/she did not go to clinic.) 
 
In general, Do you follow any guidelines when prescribing and monitoring 
Valganciclovir?  
I don’t know. I’m not sure (laughs). 
-  if so which one and do you follow accurately or do you deviate?  
(This question was not asked because he/she answered that he/she did not know if 
he/she used any guidelines.) 
- Do you have specific reasons for this? 
(This question was not asked because he/she answered that he/she did not know if 
he/she used any guidelines.) 
 
Do you communicate with the GP and expect them to participate in monitoring this 
therapy? 
I have never sent anyone home on it. In this week (laughs). So I’m not sure. I don’t know 
whether they monitor it. I imagine they would, and you would have to speak to them..(pause) 
I think they would have to agree to do that. I have not had to do that, so I’m not sure. 
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- How is this communication documented? 
(This question was not asked because he/she did not know if he/she should 
communicate with the GP.) 
 
If you identify a prescribing-error or instances where the treatment is not optimised, 
what do you do, and  how and where do you document this? 
If there is an error with the prescription I would make sure the right thing is prescribed, and 
what was wrong is crossed of. I suppose you should fill out an incident report about it, cause 
there have been an error. And you should let the senior doctors know that there has been 
given incorrectly or prescribed incorrectly. I would probably let the nurse in charge know 













Interview with renal senior doctor 
 
Prescribing 
What are the patient criteria for starting Valganciclovir prophylaxis (in transplant 
patients)?  
At the moment for renal and sometimes renal/pancreas transplants all patient except D-/R- 
will get valganciclovir.  
 
When during the transplant process is the Valganciclovir prophylaxis treatment 
initiated? 
It is usually initiated at day 1. It is often written up as they start, when they are called in and 
have their first initially kardex is written, sometimes it is delayed to day 1, cause there might 
be some misinformation about the viral status. Anything later than that that is a problem. It is 
certainly picked up before they go home.  
 
Does every patient with normal kidney function get the same dose, or do other factors 
influence dose adjustments?   
None of our patients have normal kidney function. So, all prescriptions are based on 
Cockcroft-Gault creatinine clearance. There will be occasions where patients have 
neutropenia that might mean that they come off Valganciclovir early or have a reduced dose 




- If other factors are considered, are prescribers supported through some form of 
guidelines or is it entirely independent clinical judgement? 
(This question was not asked because he/she did not answer any other factors.) 
 
 
How do you decide the dose for a person with renal impairment? 
(This question was not asked because it was already answered) 
 
Which formula do you use to calculate Creatinine clearance?  
(This question was not asked because it was already answered) 
 
Do you use eGFR for informing your prescribing decisions on Valganciclovir?  
No 
 
Do you ever use valganciclovir oral solution? 
- If yes, In which cases?  
I haven’t yet, but I know it is available for people with Cockcroft-Gault creatinine 
clearance less than 10 ml/min. There are patients who don’t like swallowing tablets and 
we would use it in that situation, but I have not personally  had a patient in that 





What is the treatment duration?  
At the moment we do six months or 200 days.  
 
Monitoring 
When monitoring: Which lab tests are done and how often?  
Monitoring renal function. It depends, some patients we monitor..we look for CMV-PCR 
depending on status. If they were recipient (CMV) negative and there was a clinical suspicion 
of a CMV infection we would check for that, but that is not routinely monitored in patients on 
prophylaxis. White blood cell counts is important. And there might be dose adjustments or 
early sesation on valganciclovir in case of neutropenia. The other monitoring liver function 
test goes on anyways. 
- Does the frequency of monitoring change after adjusting doses? 
(This question was not asked) 
How do you adjust the dose in renal impaired patients?   
Depending on their Cockcroft-Gault creatinine clearance.  
 
- Would you change the dose if it wasn't optimal according to blood tests at one 
occasion? Or do you wait to see if there is a trend?  
It depends. In varying occasions if you see patient who is right on the edge of moving 
into the next group and then you are not going to see them again for the next couple of 
weeks then I would. It is easier for them to get it sorted out then and there.  
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Usually that is because you know if you see them on the morning, you know that they 
will not get the creatinine back before this evening. So when looking at the trend, I’m 
predicting that their CrCl will push them into the next group. So I can tell them to 
increase the dose, and at evening when the results comes back I phone them and 
say:”No, actually don’t, stick to the original dose you were on”. 
 
-  Do you use literature such as for example BNF or guidelines, or do you just use 
your memory when adjusting doses?  
We got big post-its stuck on the OPD (out-patient department?) But we use Cockcroft-
Gault to find CrCl. 
 
In general, Do you follow any guidelines when prescribing and monitoring 
Valganciclovir? 
We use the guidelines based on Cockcroft-Gault. 
-  If so which one and do you follow accurately or do you deviate? 
 You might call it deviate if you predict CrCl, but I would call it pre-emptily treating. 
Our previous orders would suggest that the most likely risk is lagging behind, so we 
have to make sure the prescription matches the level of function. 
- Do you have specific reasons for this? 




Do you communicate with the GP and expect them to participate in monitoring this 
therapy? 
No, not really because we see the patients so frequently at the clinic in the first time. So to ask 
the GP to take on additionally monitoring would most likely only complicate matters.  
- How is this communication documented? 
(This question was not asked because he/she did not answer that he/she communicated with 
the GP.) 
 
If you identify a prescribing-error or instances where the treatment is not optimised, 
what do you do, and  how and where do you document this? 
If it is a prescribing error in that a patient is on a certain dose of valganciclovir and the blood 
results come back and show that the creatinine has dropped and the patients is getting to much 
valganciclovir that’s not necessarily a prescribing error it’s just that their function has 
changed and you need to adjust either up or down. So if someone has failed to recognised 
improving function and make a change, I would change the prescription. I certainly don’t 
Datix® that sort of things. Cause I think Datix® would just get bumped down (laughs), cause 









Interview with renal middle grade doctor 
 
Prescribing 
What are the patient criteria for starting valganciclovir prophylaxis in transplant 
patients?  
In this unit then all other than CMV-negative donor and CMV-negative recipient is the only 
patient group that isn’t routinely started on valganciclovir. 
 
When during the transplant process is the valganciclovir treatment initiated? 
Immediately. 
- Immediately after the transplant?  
Yes  
 
Does every patient with normal kidney function get the same dose, or do other factors 
influence dose adjustments?   
There is a protocol on our webpage (edren.org) which we follow based on the patients weight 
and CrCl, which tells us the exact regiment for Valganciclovir 
 
- If other factors are considered, are prescribers supported through some form of 
guidelines or is it entirely independent clinical judgement? 




How do you decide the dose for a person with renal impairment? 
By consulting the algorithm. 
 
Which formula do you use to calculate creatinine clearance? 
Cockcroft- Gault 
 
Do you use eGFR for informing your prescribing decisions? 
For Valganciclovir, No! 
 
Do you ever use valganciclovir oral solution?  
Yes 
- If yes, In which cases?  
If the patient is unable to take tablets but able to take the solution. 
 
What is the treatment duration? For how long is valganciclovir prescribed? 








When monitoring: Which lab tests are done and how often?  
The patient can get CMV-PCR, and it tends to varies how often depending on the clinical 
situation. 
- Does the frequency of monitoring change after adjusting doses? 
The frequency of monitoring will be change more with the clinical picture rather than change 
in dose of the Valganciclovir 
 
How do you adjust the dose according to creatinine clearance in renal impaired patient? 
- Would you change the dose if it wasn't optimal according to blood tests at one 
occasion? Or do you wait to see if there is a trend?  
(This question was added after this interview) 
      -   Do you use literature such as for example BNF or guidelines, or do you just use     
your memory?  
I would use edren.org 
Do you follow any guidelines?   
Yes, guidelines on edren.org 





- Do you have specific reasons for this? 
(This questions was not asked) 
 
Do you communicate with the GP and expect them to participate in monitoring this 
therapy? 
I think normally CMV we will check here at the transplant clinic rather than to get the GP to 
check. 
- How is this communication documented?  
That’s probably unclear 
 
If you identify a prescribing-error or instances where the treatment is not optimised, 
what do you do and how do you document this? 
You aim to address the problem. You document accurately what’s happened, and what you 
are going to do about it and you communicate either verbally or in writing depending on the 
urgency on the situation with the relevant people involved. The aim being to correct it for that 







Interview with renal Junior doctor  
 
Prescribing 
What are the patient criteria for starting Valganciclovir prophylaxis in transplant 
patients?  
As far as I am aware it is either patient who are CMV-positive before starting immune 
suppression or receiving organ from a CMV-positive donor. 
 
When during the transplant process is the treatment initiated? 
The day after the transplant 
 
Does every patient with normal kidney function get the same dose, or do other factors 
influence dose adjustments?   
Essentially we start with Valganciclovir (noise) mg three times a week when the patient  
gets a new kidney. And then as the patients renal functions improves and recovers  
over a period of days, the frequency of the dose increases. So it depends on the renal  
function, and usually Valganciclovir require a steady dose increase as the graft starts 
to work 
 
- If other factors are considered, are prescribers supported through some form of 
guidelines or is it entirely independent clinical judgement? 
We got a website with a protocol that tells us exactly what to do. www.edren.org 
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How do you decide the dose for a person with renal impairment? 
You calculate their eGFR by using their weight, age and their CrCl 
 
Which formula do you use to calculate creatinine clearance? 
I think we use the Cockcroft-Gault equation, I can’t remember. 
 
Do you use eGFR for informing your prescribing decisions?  
(Did not ask that question since he/she already said he/she used is above) 
 
Do you ever use valganciclovir oral solution? 
- If yes, In which cases? 
No tablets. 
 
What is the treatment duration? For how long is valganciclovir prescribed? 




When monitoring: Which lab tests are done and how often?  
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For CMV reactivation we do a CMV PCR, So thats a PCR to determine the numbers of copies 
of CMV pr ml blood, and how often that’s done varies on the patient. For the patients that are 
unwell or are known to have reactivation it’s done maybe twice a week, and for the patients 
that haven’t had any problems with reactivation maybe done every few month or every sixth 
month. We would certainly have it done in every CMV-positive patient that becomes unwell. 
- Does the frequency of monitoring change after adjusting doses? 
I don’t think so. 
 
How do you adjust the dose according to creatinine clearance in renal impaired 
patients?  
- Would you change the dose if it wasn't optimal according to blood tests at one 
occasion? Or do you wait to see if there is a trend? 
(This question was added after this interview) 
- Do you use literature such as for example BNF or guidelines, or do you just use     
your memory?  







Do you follow any guidelines?  
Yes I do what the pharmacist tells me most of the time(laughs) 
-  if so which one and do you follow accurately or do you deviate?  
I follow what the pharmacist tells me(laughs) 
- Do you have specific reasons for this? 
(This questions was not asked) 
 
Do you communicate with the GP and expect them to participate in monitoring this 
therapy? 
No. We will communicate with the GP and tell them which drugs they are on, but I’m not 
sure that we would expect them to participate in the monitoring. 
 
- How is this communication documented? 







If you identify a prescribing-error or instances where the treatment is not optimised, 
what do you do and how do you document this? 
With a prescribing-error you would correct it, and you write in the notes what have happened. 
And if there is any detriment to the patient you would tell the patient at the same time, so 
they’re informed that there has been an error. Also I would make sure that all the doctors 





















Interview; Mapping the process of administrating Valganciclovir after interviewing 
nurses. 
 
Interview with senior nurse 
 
How are nurses made aware of new prescriptions? Is the nurse notified? Or do they 
have to check the kardex? 
As in if something is prescribes for the patient. The doctors always come and hand it you. 99 
% of the time. And let you know what this patient needs whatever at whatever time. 
 
Who orders from pharmacy? (Only nurses? All nurses?) 
Orders for individual patients are done by the trained nurses. Also sometimes the pharmacist 
is checking things, and if he/she sees that you know [name] needs Paracetamol and he/she’ll 
order it for him. [The pharmacist] will do that and get you to sign it off (pause). The 
registered nurses do the ordering for the pharmacy as well. For our stocks and cupboards. So 
the nurses you know do all (pause) mostly. 
 
- How are the orders documented at the ward?  
We have a sheet. It’s like a form with two weeks sheet. 
And every now and then the pharmacists will come up to the ward and maybe re-amp 
your cupboards and see in the cupboard what we have been using a lot of, and what 
have been stopped. Cause drugs change all the time. So we tend to re-amp the 
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cupboard every now and then, and then the stocks reflect your sheets.(pause) So it’s a 
pharmacy order form that we do twice a week. And on it you got your drugs and how 
many we think we need to top up of the Paracetamol...Ten boxes of Prednisolon or 
whatever..And there is a guide as to what they think you should have as a minimum 
order.. so maybe ten boxes of MMF. Ten boxes of Tacro. 15 of Paracetamol.  
 
What is the process of drug administration? (How does the drug rounds happen?) 
Well.. I suppose you have seen these tabards that we now have to wear. 
Years ago we had a lovely big drug trolley, that we invested a lot of time  and effort into 
nurses backs. And everything was at your level and you went round and everybody knew you 
were on a drug round so they knew not to bother you cause you had a big trolley of drugs in 
front of you. And you would basically dispense at this nice high table, and before we moved 
to the new hospital we got the POD-system? Every patient has a locker with their drugs in. 
And of course the patient locker has to be in a certain level, with years a bunch of them have 
been broken. The majority of the drugs you dispense..all the drugs you dispense is in the 
patient’s locker. And nobody knows you are on a drug round, cause they can’t see you.so 
there is a lot of interruption. Mistakes in general over the years have escalated. So we got 
these lovely tabards that we now wear, so that people know not to speak to us cause obviously 
we are on a drug round.. (pause) Which I think is wonderful because we needed to do 
something. But if we just bring back the old trolley we would get away from all that, plus you 
are back and forth to the cupboards half a dozen times to get restocks of things, and somebody 
else has got the cupboard key and..you know.. It took me an hour to do a whole ward of drugs 
years ago, now it takes me an hour and a half to do six patients.. And I am quite appalled of 
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how long time it takes in the morning. And that is not just the self education of patients..that 
is the time in itself.. but it is trying to find the key and the geographical layout  of where we 
are..(pause) It is not ideal. And we have no base cause the patients bed tables are cluttered, the 
lockers are cluttered   
  
- Do you know about any measures initiated to improve medicine safety in 
administration?   
Well, At the minute I would say we got these tabards that has been brought in the last wee 
while. This is to try and basically improve errors, so you are not interrupted constantly. So 
that’s one thing. And we used to have education-coordinators who would arrange..so if 
you had some junior who struggled, then they could be supervised. You could be 
mentored slightly more. And those roles are all kind of gone. But if you worry about 
anyone and felt they needed a bit more information there are courses on drug 
administration...(Pause) There is drug administration courses that the nurses can do to try 
to give them a bit more confidence with lings like that. 
 







If an administration error happens, who is notified, and where is it documented? 
If you discover that you have made a mistake..or someone comes to you and have made a 
mistake the first thing you do is check the patient. And then you would let the doctors know. 
Nine out of 10 times you would discuss it with the patient, and let them know. And they all 























Interview with junior nurse 
 
How are nurses made aware of new prescriptions? Is the nurse notified? Or do they 
have to check the kardex? 
Ehm.. They are pretty good at telling us that there is a new drug on the kardex. Sometimes 
they do escape telling you, but you are pretty good at picking it up yourself. But the doctors 
tell you about 99 % of the times. 
  
Who orders from pharmacy? (Only nurses? All nurses?) 
We have like routine pharmacy, we to every two nights on night shifts were we have just out 
standard in the cupboards and a nurse will order that, however if we need a drug we do not 
stock in the ward a nurse will just order with a IPS(?) down to pharmacy. So it is only nurses 
who can order drugs. Or the pharmacist. 
 
- How are the orders documented at the ward?  
We have our pharmacy sheet that we send down for the main stock. And for 
independent patients it is all in the IPS book. 
 
What is the process of drug administration? (How does the drug rounds happen?) 
 We have just implemented a new system with the tabard system with these tabards that says 
do not interfere the nurses. And what we do is that we have two out of tree nurses doing that 
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at the time, and there is always a spare nurse walking about.(pause) So it’s just the tabards. 
We try to get no one to disturb us, so that we won’t make mistakes. So that system is quite 
good. 
 
- Do you know about any measures initiated to improve medicine safety in 
administration?   
Tabards. Because there were a few mistakes before they were brought in, so that’s why 
we brought them in. So that people are aware of not to speak to us when we have them 
on.  
 
Are you aware of the precautions required for handling this medicine(valganciclovir)? 
Yeah, you mean like using gloves and don’t come in to contact with it? It is quite toxic. Also 
when we are finished with it we have to put it into a special sharps bin. It will be the 
pharmacist and the nurses who educate the patient on this. 
 
If an administration error happens, who is notified, and where is it documented? 
For errors made nurses have to document in the notes. We also have to inform the doctors. 
And also we have to fill out an incident report on the computer, and it gets sent to important 

































Edren.org – Transplant Handbook - CMV 
 
Valganciclovir  
Criteria for patient selection 
For prevention of CMV disease in high risk transplant patients identified as 
follows: 
 
Renal and Simultaneous kidney-pancreas transplant (SKP) - All 
transplant recipients except CMV –ve recipients of CMV –ve donors 
 
Valganciclovir has replaced Ganciclovir for prevention of CMV disease.  
Prescriptions will be initiated in hospital within 10 days of transplantation.  
Therapy will be continued in primary care for up to a total of 180 days 
treatment for which a shared-care protocol will be provided. 
 
The initial valganciclovir dose is dependent on renal function as shown in 





>60 900mg od 
40 to 59 450mg od 
25 to 39 450mg every 2 days 
10 to 24 450mg twice weekly 
<10 
100mg three times weekly 
after dialysis 
     
Valganciclovir is available as 450mg tablets (pink) or as an oral solution 
and the brand name is Valcyte .  The tablets should be taken with food 
and not broken or crushed. 
     
FBC and LFTs must be monitored daily during therapy. 
Leucopenia can occur with valganciclovir treatment and this is a common 
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cause for discontinuing the drug prematurely. 
 
Note: Surveillance for CMV post - transplant is not performed routinely in 
the Unit. 
 
Investigation of any episode of illness which might be CMV 
related, at any stage following a transplant operation. 
  
 An EDTA (9 ml or 3 x 2.5 mls sample for CMV should be sent to 
Virology whenever is clinically relevant. ON request form include 
details of illness (e.g. pyrexia or hepatitis etc.) Request CMV PCR 
and CMV culture. Please try to ensure samples reach Virus Lab by 
midday. The rapid culture may provide an answer sooner than PCR 
in some cases. 
 It will often be appropriate to send respiratory or other samples to 
virology - bronchoalveolar lavage or induced sputum for 














Edren.org – Immunosuppression protocol – October 2009 (Edinburgh, 
Inverness, Aberdeen, Dundee, Fife) – CMV prophylaxis 
All patients receiving a kidney and/or pancreas transplant except CMV negative recipients of 
CMV negative grafts should receive prophylaxis with Valganciclovir (dosing according to 
eGFR) 
 
Duration of prophylaxis should extend to 6 months (180 days) 
 
Protocol for in-patient management following liver transplantation. 
Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh – Control of 
infections – Prophylaxis – Anti-viral – CMV 
 
High risk recipients i.e. CMV negative patients receiving a CMV positive donor and all 
retransplants, 
will receive oral valganciclovir 900mg once daily commencing at day 7 and 




Protocol for out-patient management following liver transplantation. 
Scottish Liver Transplant Unit, Royal Infirmary of Edinburgh – 
Management of specific problems – CMV 
If patient is suspected of having CMV disease send 10ml red (EDTA) tube to virology for 
CMV-DNA by PCR rapid culture. If appropriate can also send tissue (gastric, colonic, liver 
biopsy material) for CMV culture – discuss cultures beforehand with virology (Duty 
Virologist, REI bleep 5981).  Quantitative PCR for blood CMV-DNA is also available. 
 
If CMV disease is confirmed the treatment is IV ganciclovir 5 mg/kg/bd (reduce dose in renal 
failure – discuss with Pharmacist on bleep 5132).  If patient is well and lives sufficiently close 
to the transplant unit or their referring hospital to visit twice daily, it may be possible to 
administer this IV course as an out patient.  Alternatively, consider oral valganciclovir 900 
































Collecting real data from a snapshot in the clinic. 
Inclusion criteria; All post-transplanted pasients on Valganciclovir prophylaxis visiting the clinic at the day of collecting data. 




dose Given dose 
Time 
since Tx 






          
  






          
  






          
  






          
  






          
  






          
  






          
  






























Questionnaire about staff opinion about risks of errors in prescribing, administration and monitoring of Valganciclovir.  
  
I think there 
is a risk of 
errors that 
will always 
lead to harm 
I think there is a 
risk of errors  
that might lead 
to harm in some 
cases 
I think there is a 
risk of errors that 
will never lead to 
harm 
I think there is no 
risk of errors (with 
or without harm 
as consequence) 
Comments 
Deciding if Valganciclovir should be 
prescribed           
Deciding when to start treatment       
  
  
Deciding dose for patients with 
normal kidney function           
Deciding dose for renally impaired 
patients           
Calculating Creatinine clearance           
Choosing correct drug formulation           
Deciding treatment duration           
            
Administering right drug           
Administering at right time           
            
Adjusting dose after measurement 
of Creatinine clearance           
Collaborate with GPs on treatment 






























    Patient 1  Patient 2 Patient 3 Patient 4 
  Initials         
  Sex         
  Age         
  weight         
Filled out only at 
the first visit 
Appropriate prescribing for  
CMV- status         
visit 1 Type of transplantation         
Day _ since Tx Pharmacicst intervention         
  1=Interaction         
  2=Dose increased   
     3=Dose decreased   
   
      visit 2 Creatinine         
Day _ since Tx Creatinine clearance         
  Pharmacist Intervention         
      visit 3 Creatinine         
Day _ since Tx Creatinine clearance         
  Pharmacist Intervention         
      visit 4 Creatinine         
Day _ since Tx Creatinine clearance         
  Pharmacist Intervention         
      visit 5 Creatinine         
Day _ since Tx Creatinine clearance         
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Critically review and evaluate the 
processes in the prescribing, 
administration and monitoring of 
valganciclovir for cytomegalovirus 






 Define the processes for prescribing, administering and 
monitoring of valganciclovir use for CMV prophylaxis.
 Identify the procedures available to support decisions in 
the use of valganciclovir.
 Characterise the harm assessment based on data from 
prospective audit
 Identify potential and actual risks associated with use of 
valganciclovir
 Identify pharmaceutical interventions. 
 Critically evaluate opportunities for quality improvement 








 Map the process for prescribing, administation and 
monitoring of valganciclovir based on interviews with 
doctors and nurses.
 Collect data regarding adverse drug events associated 
with valganciclovir from Datix and pharmacist 
interventions.
 Observe and evaluate process in out-patient setting for 
prescribing valganciclovir. 
 Lastly I will present results and quality improvement 
suggestions to a multidisciplinary team. 
 
 
 
 
